CJC-1295 / Ipamorelin vs Tesamorelin
CJC-1295/Ipamorelin and Tesamorelin both target growth hormone secretion but through different mechanisms and with different research profiles. CJC-1295 is a modified GHRH analog with a Drug Affinity Complex (DAC) modification that extends its half-life substantially by binding to albumin, while Ipamorelin is a selective ghrelin receptor agonist that amplifies GH pulses without significant cortisol or prolactin elevation. Together they create synergistic GH secretagogue activity. Tesamorelin is a synthetic analog of full-length GHRH(1-44) that stimulates physiological GH release while preserving the normal feedback mechanisms of the GH axis. Researchers studying growth hormone biology, body composition, or visceral fat metabolism frequently compare these compounds to determine which approach better fits their experimental design.
CJC-1295 / Ipamorelin
GHRH analog (CJC-1295) plus GHRP (Ipamorelin) blend
Tesamorelin
Full-length GHRH(1-44) synthetic analog
At a Glance
Key research profiles for each compound.
CJC-1295 / Ipamorelin
GHRH analog blend studied for pulsatile growth hormone secretion research
Class
GHRH analog (CJC-1295) plus GHRP (Ipamorelin) blend
Mechanism
GHRH receptor agonism plus ghrelin receptor agonism
Half-Life
CJC-1295 with DAC approximately 6 to 8 days; Ipamorelin 2 hours
Research Area
GH secretion, IGF-1 modulation, body composition research
- CJC-1295 investigated as a long-acting GHRH analog with DAC modification
- Ipamorelin studied for selective GHRP activity without significant cortisol elevation
- Blend examined for synergistic GH pulse amplification in preclinical models
- Documented effects on IGF-1 levels and lean body composition in animal studies
Tesamorelin
Full-length GHRH(1-44) analog studied for visceral fat reduction and GH secretion
Class
Full-length GHRH(1-44) synthetic analog
Mechanism
GHRH receptor agonism, physiological GH pulse stimulation
Half-Life
Approximately 26 minutes in human pharmacokinetic studies
Research Area
GH secretion, visceral fat metabolism, body composition
- Studied as a synthetic analog of full-length GHRH(1-44) with trans-2 hexenoic acid modification
- Investigated for visceral adipose tissue reduction in HIV-associated lipodystrophy models
- Examined for GH pulse amplification while preserving physiological GH feedback
- Documented IGF-1 elevation without sustained GH elevation beyond physiological range
Side-by-Side Comparison
Key research parameters compared directly.
| Feature | CJC-1295 / Ipamorelin | Tesamorelin |
|---|---|---|
| Compound Class | GHRH analog plus GHRP blend | Full-length GHRH(1-44) analog |
| Primary Mechanism | GHRH receptor plus ghrelin receptor dual agonism | GHRH receptor agonism only |
| Half-Life | CJC-1295 6 to 8 days; Ipamorelin 2 hours | Approximately 26 minutes |
| GH Feedback Preservation | Partial, extended stimulation pattern | Preserved physiological feedback loop |
| IGF-1 Elevation | Documented in animal and human studies | Documented, within physiological range |
| Visceral Fat Research | Body composition research in models | FDA-approved for HIV lipodystrophy (Egrifta) |
| Cortisol Effect | Minimal with Ipamorelin component | No documented cortisol elevation |
| Clinical Status | Research use; compounding history in wellness | FDA-approved drug (Egrifta) with Phase 3 data |
Research Deep-Dive
CJC-1295 / Ipamorelin
CJC-1295 (with DAC) is a synthetic GHRH analog modified with a Drug Affinity Complex that allows it to bind covalently to albumin, extending its half-life from minutes to approximately 6 to 8 days. This results in a sustained elevation of GH pulse amplitude over time rather than the brief pulse stimulation seen with unmodified GHRH. Ipamorelin is a pentapeptide selective agonist of the ghrelin receptor (GHS-R1a) that amplifies GH pulses with high selectivity and minimal effect on cortisol, prolactin, or ACTH secretion. When combined, CJC-1295 and Ipamorelin create synergistic stimulation of GH secretion through two complementary receptor pathways, making their blend a common tool for GH secretagogue research.
View CJC-1295 / Ipamorelin →Tesamorelin
Tesamorelin (TH9507) is a synthetic analog of full-length human GHRH(1-44) stabilized by the addition of a trans-2 hexenoic acid moiety at the N-terminus. Unlike CJC-1295 with DAC, Tesamorelin does not bypass the physiological GH feedback loop. It stimulates GH release from the pituitary in a manner that preserves somatostatin-mediated negative feedback, meaning it amplifies GH pulses without causing sustained supraphysiological GH levels. Tesamorelin received FDA approval (as Egrifta) in 2010 for the treatment of HIV-associated lipodystrophy, making it one of the few growth hormone secretagogues with Phase 3 clinical trial data and regulatory approval. Its visceral fat reduction profile in lipodystrophy models has also made it a subject of broader body composition research.
View Tesamorelin →Research Context
CJC-1295/Ipamorelin and Tesamorelin represent different approaches to the same GH secretagogue research space. CJC-1295/Ipamorelin offers dual-receptor, longer-duration stimulation suited to research designs examining sustained GH elevation and IGF-1 effects. Tesamorelin offers a more physiological stimulation pattern with preserved feedback regulation, supported by human clinical data, and is particularly relevant to visceral fat and body composition research given its regulatory history.
Frequently Asked Questions
Related Comparisons
Research Stacks
Source Both Compounds
CJC-1295 / Ipamorelin and Tesamorelin are both available from Spartan Peptides at ≥98% HPLC-verified purity. Domestic US supply, same-day dispatch before 2 PM. All products for in-vitro research use only.
All compounds are strictly for in-vitro research use only and not intended for human consumption.